1. Search Result
Search Result
Results for "

proliferative

" in MedChemExpress (MCE) Product Catalog:

836

Inhibitors & Agonists

2

Screening Libraries

2

Fluorescent Dye

12

Biochemical Assay Reagents

18

Peptides

12

Inhibitory Antibodies

118

Natural
Products

1

Recombinant Proteins

21

Isotope-Labeled Compounds

1

Antibodies

5

Click Chemistry

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15910
    5-BrdU
    Maximum Cited Publications
    77 Publications Verification

    BrdU; 5-Bromo-2'-deoxyuridine; BUdR

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Cancer
    5-BrdU (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.
    5-BrdU
  • HY-17538
    ZLN005
    45+ Cited Publications

    PGC-1α Autophagy Metabolic Disease
    ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) .
    ZLN005
  • HY-W010737

    5'-GTP disodium salt

    Exosomes Endogenous Metabolite MicroRNA Metabolic Disease
    Guanosine 5'-triphosphate (5'-GTP) trisodium salt is a G protein (G proteins) signaling activator and a high-energy precursor in the biosynthesis of nucleotide units in DNA and RNA. Guanosine 5'-triphosphate trisodium salt can promote myogenic cell differentiation by upregulating miRNA (miR133a, miR133b) and myogenic regulatory factor expression, and by inducing human myogenic precursor cells to release exosomes containing guanosine molecules. Guanosine-5'-triphosphate disodium salt holds promise for research in biosynthesis and skeletal muscle regeneration .
    Guanosine-5'-triphosphate disodium salt
  • HY-131328
    Pirtobrutinib
    5 Publications Verification

    LOXO-305

    Btk Cancer
    Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .
    Pirtobrutinib
  • HY-N0181
    Ergosterol
    3 Publications Verification

    Endogenous Metabolite Inflammation/Immunology
    Ergosterol is the primary sterol found in fungi, with antioxidative, anti-proliferative, and anti-inflammatory effects.
    Ergosterol
  • HY-148185

    KL610023

    ADC Payload Cancer
    T01-1 is an anticancer agent (camptothecin derivative) with good anti-proliferative activity .
    T01-1
  • HY-15577
    GSK3787
    15+ Cited Publications

    PPAR Cancer
    GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6.
    GSK3787
  • HY-B0664

    Win35833

    PPAR Metabolic Disease
    Ciprofibrate (Win35833) is a potent peroxisome proliferator and increases the phosphorylation level of the PPARalpha . Ciprofibrate acts as an orally active hypolipidaemic agent and can be used for the research of primary hyperlipidaemias .
    Ciprofibrate
  • HY-148491

    Casein Kinase Cancer
    CSNK1-IN-2 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC50 values of 44 nM. CSNK1-IN-2 can be used for the research of proliferative disorders .
    CSNK1-IN-2
  • HY-147135
    MYF-03-69
    1 Publications Verification

    TEAD-IN-3

    YAP Apoptosis Cancer
    MYF-03-69 (TEAD-IN-3) is a covalent and irreversible TEAD inhibitor with IC50s of 385, 143, 558 and 173 nM for TEAD1, TEAD2, TEAD3 and TEAD4. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity (IC50 = 56 nM) and up-regulates apoptosis gene BMF. MYF-03-69 selectively inhibits mesothelioma cancer cells with defective Hippo signaling. MYF-03-69 can be used for the study of malignant pleural mesothelioma (MPM) .
    MYF-03-69
  • HY-15948
    Kif15-IN-1
    4 Publications Verification

    Kinesin Cardiovascular Disease Inflammation/Immunology Cancer
    Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.
    Kif15-IN-1
  • HY-153344
    FX-909
    1 Publications Verification

    PPAR Cancer
    FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer .
    FX-909
  • HY-N3755

    Estrogen Receptor/ERR Cancer
    Dihydroresveratrol, a potent phytoestrogen, is a hormone receptor modulator. Dihydroresveratrol exhibits proliferative effects in androgen-independent prostate and breast cancer cells at picomolar and nanomolar concentrations .
    Dihydroresveratrol
  • HY-148489
    CSNK1-IN-1
    1 Publications Verification

    Casein Kinase Cancer
    CSNK1-IN-1 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC50 values of 21 μM. CSNK1-IN-1 can be used for the research of proliferative disorders .
    CSNK1-IN-1
  • HY-151289

    TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC50 value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .
    ALK5-IN-34
  • HY-133121

    Apoptosis WDR5 Cancer
    WDR5-IN-1 is a potent and selective WD repeat domain 5 (WDR5) inhibitor, with a Kd of <0.02 nM. WDR5-IN-1 inhibits MLL1 histone methyltransferase (HMT) activity with an IC50 of 2.2 nM. WDR5-IN-1 diminishes MYC recruitment at WDR5-displaced genes and exhibits potent anti-proliferative effects in CHP-134 (neuroblastoma) and Ramos (Burkitt’s lymphoma) lines .
    WDR5-IN-1
  • HY-130479

    Adiponectin Receptor PPAR PGC-1α Sirtuin AMPK Metabolic Disease
    AdipoR agonist 1 (Compound 112254) is an agonist for adiponectin receptor (AdipoR), which activates the transcriptional regulators like peroxisome proliferator-activated receptors (PPARs), peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), and adenylate-activated protein kinase (AMPK). AdipoR agonist 1 is utilized in preventive doping research .
    AdipoR agonist 1
  • HY-148215A

    HSP Neurological Disease Cancer
    Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17 hydrochloride
  • HY-120069

    Apoptosis Cancer
    APX2009 is a specific APE1/REF-1 redox inhibitor with anticancer activities which decreases the proliferative, migratory, and invasive properties of breast cancer cell and induces apoptosis in breast cancer cell .
    APX2009
  • HY-119964

    PPAR Cardiovascular Disease
    Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides .
    Cetaben
  • HY-133095

    STAT PPAR Inflammation/Immunology
    BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity .
    BML-260
  • HY-119017

    HDAC Cancer
    SB-429201 is a potent and selective HDAC1 (IC50~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .
    SB-429201
  • HY-156285

    Histone Methyltransferase Apoptosis Cancer
    ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase .
    ZZM-1220
  • HY-B0316R

    Reference Standards Estrogen Receptor/ERR Apoptosis Others
    Avobenzone (Standard) is the analytical standard of Avobenzone. This product is intended for research and analytical applications. Avobenzone, a dibenzoylmethane compound, is one of the most widely used filters in sunscreens for skin photoprotection in the UVA band. Avobenzone is an endocrine disruptor that directly binds to estrogen receptor β and acts as an estrogen agonist .
    Avobenzone (Standard)
  • HY-164082

    Clofenapate methyl ester; MCP

    PPAR Metabolic Disease Cancer
    Methyl clofenapate (Clofenapate methyl ester; MCP) is a peroxisome proliferator, which can induce hypolipidemia, peroxisome proliferation, and hepatocarcinogenesis .
    Methyl clofenapate
  • HY-14831
    Arhalofenate
    1 Publications Verification

    MBX 102; JNJ 39659100

    PPAR Metabolic Disease
    Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
    Arhalofenate
  • HY-101746

    PPAR Metabolic Disease
    GSK376501A is a selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator for the treatment of type 2 diabetes mellitus .
    GSK376501A
  • HY-144867

    HSP Cancer
    CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1) .
    CCT245232
  • HY-145025

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-129371

    ADC Linker Cancer
    SPDV is a cleavable ADC linker used for diagnosis and treatment of cancer or B cell proliferative diseas.
    SPDV
  • HY-N8239

    Others Others
    Cepharanoline is a compound isolated from Stephania cepharantha Hayata. Cepharanoline has proliferative activities .
    Cepharanoline
  • HY-146506

    Microtubule/Tubulin Cancer
    isoCA-4, a Combretastatin A4 derivative, is a tubulin polymerization inhibitor. isoCA-4 has anti-proliferative activities .
    isoCA-4
  • HY-117810

    JAK Inflammation/Immunology
    JAK2-IN-1 (eExample 2) is a JAK2 inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .
    JAK2-IN-1
  • HY-160543

    ADC Payload Topoisomerase Cancer
    Exatecan-amide-CH2-O-CH2-CH2-OH (Compound 4) is a derivative of Exatecan (HY-13631). Exatecan-amide-CH2-O-CH2-CH2-OH can be used for the research of cell proliferative diseases such as cancer .
    Exatecan-amide-CH2-O-CH2-CH2-OH
  • HY-178990

    Sirtuin Cancer
    SIRT6-IN-5 (Compound 25) is a selective and safe SIRT6 inhibitor (IC50 = 18.91 µM). SIRT6-IN-5 can enhance the anti proliferative effect of chemotherapy agents. SIRT6-IN-5 can be used in the research of cancer, such as breast cancer .
    SIRT6-IN-5
  • HY-162427

    Syk Endocrinology
    NMS-0963 (compound 1) is an inhibitor of spleen tyrosine kinase (SYK) with an oral activity and IC50 value of 3 nM. NMS-0963 inhibits BaF3-TEL/SYK cell line proliferative at 27 nM .
    NMS-0963
  • HY-122989

    DYRK Inflammation/Immunology
    Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC50= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .
    Aristolactam BIII
  • HY-153011

    ROCK ERK GSK-3 Cardiovascular Disease Neurological Disease
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research .
    ROCK-IN-5
  • HY-142671

    ATM/ATR Cancer
    ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .
    ATR-IN-5
  • HY-142672

    ATM/ATR Cancer
    ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .
    ATR-IN-6
  • HY-145026

    ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 4
  • HY-145027

    ERK Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 5
  • HY-151609

    PARP Cancer
    PARP7-IN-12 is a potent PARP7 Inhibitor with an IC50 value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .
    PARP7-IN-12
  • HY-112486G

    Megakaryocytes/platelets inducing agent (GMP)

    Cyclin G-associated Kinase (GAK) Cardiovascular Disease
    TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .
    TA-316 (GMP)
  • HY-15949

    Kinesin Cardiovascular Disease Inflammation/Immunology Cancer
    Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.
    Kif15-IN-2
  • HY-133777

    PPAR Cancer
    Ciprofibrate impurity A is an impurity of Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha .
    Ciprofibrate impurity A
  • HY-116938

    Apoptosis Cancer
    Farnesiferol C is a sesquiterpene coumarin with anti-cancer activity. Farnesiferol C inhibits the proliferative and apoptotic of AGS cells .
    Farnesiferol C
  • HY-108161

    Interleukin Related Others
    LF 1695 is an immunomodulator. LF 1695 enhances the proliferative response of T cells by increasing the production of IL2 (interleukin-2) or the expression of the IL2 receptor. LF 1695 also increases CONA-induced inhibitory activity in human lymphocytes. LF 1695 can be used to study the proliferative and inhibitory activity of T cell subpopulations, as well as their role in immune regulation .
    LF 1695
  • HY-N8477

    NO Synthase Inflammation/Immunology
    Isolupalbigenin is an inhibitor of NO. Isolupalbigenin has anti-proliferative activity on HL-60 cells with an IC50 of 5.1 μM .
    Isolupalbigenin
  • HY-N10699

    Others Cancer
    6-Methoxykaempferol is a flavone that can be found in brazilian propolis. 6-Methoxykaempferol shows anti-proliferative activity for cancer cells .
    6-Methoxykaempferol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: